

Andrea R Sabbatini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8778660/publications.pdf>

Version: 2024-02-01

17
papers

418
citations

840776

11
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

809
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of two selective A ₁ receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats. <i>British Journal of Pharmacology</i> , 2020, 177, 346-359.	5.4	5
2	Estrogen-related mechanisms in sex differences of hypertension and target organ damage. <i>Biology of Sex Differences</i> , 2020, 11, 31.	4.1	62
3	Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1074-1082.	2.8	76
4	The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects. <i>Gene</i> , 2018, 646, 129-135.	2.2	7
5	Effects of leptin and leptin receptor SNPs on clinical- and metabolic-related traits in apparent treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 74-80.	1.5	10
6	Matrix metalloproteinase-2 γ 735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil. <i>Gene</i> , 2017, 620, 23-29.	2.2	10
7	Crosstalk between obesity and MMP-9 in cardiac remodelling – a cross-sectional study in apparent treatment-resistant hypertension. <i>Blood Pressure</i> , 2017, 26, 122-129.	1.5	15
8	Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2016, 18, 969-975.	2.0	20
9	A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 510-516.e1.	2.3	15
10	Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension. <i>American Journal of Hypertension</i> , 2016, 29, 245-250.	2.0	11
11	Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 397-402.	2.3	36
12	Adiponectin ϵ 1377C/G and +276G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 65-72.	2.5	10
13	An update on the role of adipokines in arterial stiffness and hypertension. <i>Journal of Hypertension</i> , 2015, 33, 435-444.	0.5	42
14	Predictors of Silent Myocardial Ischemia in Resistant Hypertensive Patients. <i>American Journal of Hypertension</i> , 2015, 28, 200-207.	2.0	6
15	Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. <i>Clinica Chimica Acta</i> , 2014, 433, 179-183.	1.1	31
16	Modulation of aldosterone levels by γ 344A/T CYP11B2 polymorphism and spironolactone use in resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 146-151.	2.3	23
17	Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. <i>Hypertension Research</i> , 2013, 36, 1067-1072.	2.7	39